These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824 [TBL] [Abstract][Full Text] [Related]
7. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T; Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526 [TBL] [Abstract][Full Text] [Related]
8. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
9. Considerations in boosting COVID-19 vaccine immune responses. Krause PR; Fleming TR; Peto R; Longini IM; Figueroa JP; Sterne JAC; Cravioto A; Rees H; Higgins JPT; Boutron I; Pan H; Gruber MF; Arora N; Kazi F; Gaspar R; Swaminathan S; Ryan MJ; Henao-Restrepo AM Lancet; 2021 Oct; 398(10308):1377-1380. PubMed ID: 34534516 [No Abstract] [Full Text] [Related]
10. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. Vanhoutte F; Liu W; Wiedmann RT; Haspeslagh L; Cao X; Boundy K; Aliprantis A; Davila M; Hartzel J; Li J; McGuire M; Ramsauer K; Tomberger Y; Tschismarov R; Brown DD; Xu W; Sachs JR; Russell K; Stoch SA; Lai E EBioMedicine; 2022 Jan; 75():103811. PubMed ID: 35042081 [TBL] [Abstract][Full Text] [Related]
12. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates. Behr MA; Divangahi M; Schurr E J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Meng FY; Gao F; Jia SY; Wu XH; Li JX; Guo XL; Zhang JL; Cui BP; Wu ZM; Wei MW; Ma ZL; Peng HL; Pan HX; Fan L; Zhang J; Wan JQ; Zhu ZK; Wang XW; Zhu FC Signal Transduct Target Ther; 2021 Jul; 6(1):271. PubMed ID: 34267185 [TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311 [TBL] [Abstract][Full Text] [Related]
16. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168 [TBL] [Abstract][Full Text] [Related]